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Abstract
Background: SCF (stem cell factor) is a pleiotropic cytokine exerting its role at different stages
of bone marrow development and affecting eosinophil activation, mast cells and basophil
chemotaxis and survival. The aim of the study was to assess concentration of SCF and its soluble
receptor c-kit (sc-kit) in peripheral blood of patients with asthma referring it to asthma severity
and phenotype.
Methods: The study involved 107 patients with bronchial asthma, well characterized with respect
to severity and 21 healthy controls. Concentration of SCF and sc-kit in the patients serum were
measured by ELISA method.
Results: Mean serum SCF level in the group of asthmatics (n = 88) was significantly higher as
compared to healthy controls (1010 pg/ml ± 37 vs 799 ± 33; p < 0,001). The level of SCF was higher
in patients with severe asthma as compared to patients with non-severe asthma (1054 +/- 41 pg/
ml vs 819 +/- 50; p < 0,01) and correlated with dose of inhaled glucocorticosteroids taken by the
patients to achieve asthma control (R = 0,28; p < 0,01). The mean sc-kit serum level did not differ
between asthmatic patients and healthy controls, however the level of sc-kit in non-severe
asthmatics was significantly higher as compared to patients with severe asthma and healthy
controls. In asthmatic patients (n = 63) the level of sc-kit correlated positively with FEV1%
predicted value (R = 0,45; p < 0,001) and MEF25% predicted value (R = 0,33; p < 0,01). The level
of sc-kit inversely correlated with the dose of inhaled glucocorticosteroids taken by the patients
(R = -0,26; p < 0,01).
Conclusion: Serum levels of SCF and its soluble receptor c-kit seem to be reflect asthma severity
suggesting a role for these molecules in asthmatic inflammation.
Background
Hemopoietic cytokines play a crucial role in the activation
and survival of cells involved in asthmatic inflammation.
Stem cell factor (SCF)- the c-kit ligand, although initially
was described as a mast cell growth factor [1] appeared to
be a pleiotropic cytokine exerting its role at the first stages
of bone marrow stem cells development [2], inducing
eosinophil activation [3] and basophil chemotaxis and
survival [4].
As mast cells and eosinophils are key cells in the inflam-
matory process ongoing in the airways of patients with
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asthma the role of SCF in this disease has been studied.
The expression of mRNA for SCF and its receptor c-kit
were shown to be higher in the bronchi of patients with
asthma as compared to controls [5] and serum SCF level
was higher in patients with allergic asthma [6]. SCF is also
overexpressed in nasal epithelia of patients with allergic
rhinitis [7] and in the skin of patients with atopic derma-
titis [8]. The expression of SCF is higher in nasal polyp epi-
thelial cells of aspirin hypersensitive patients in
comparison to aspirin tolerant patients and correlates
with tissue eosinophils and polyp recurrences [9]. Studies
on anti SCF therapy in mice model of asthma demon-
strated that inhibition of SCF led to reduction of eosi-
nophil accumulation in the airways, attenuation of
peribronchial remodeling and decrease in bronchial
hyperreactivity [10-12]. SCF is a cytokine exerting its role
through binding to c-kit receptor [13], which can be shed
from the cell surface and is detected in the serum as solu-
ble c-kit (sc-kit) [14].
As SCF is the cytokine acting mainly in the bone marrow,
we argue if the airway inflammation typical for asthma
may lead to increase of the level of circulating SCF. So the
aim of the study was to assess if the concentration of SCF
and its soluble receptor c-kit in peripheral blood is
increased in patients with asthma and if it correlates with
disease severity and asthma phenotype.
Methods
Patients
The study involved 107 patients with asthma and 21 con-
trols. SCF was assessed in 88 patients with asthma: 56
patients with severe and 32 patients with non-severe
asthma, and the soluble c-kit level was assessed in 63 asth-
matics: 41 severe and 22 non-severe (Table 1).
The control group for SCF consisted of 21 healthy subjects
(12 males and 9 females, mean age 35, range 21 to 46)
and the control group for c-kit consisted of 15 healthy
subjects (9 males and 6 females; mean age 34, range 21 to
45 years old) recruited from the healthy Lodz inhabitants.
Both SCF and sc-kit were assessed in 44 patients and in 15
control subjects.
Asthma was diagnosed based on history, clinical examina-
tion and spirometric evaluation according to GINA defini-
tion. Severe refractory asthma was diagnosed according to
ATS Workshop criteria which included use of oral gluco-
corticosteroids, high dose of inhaled glucocorticosteroids,
daily use of a controller drug or short-acting beta 2 ago-
nists, low respiratory function and history of exacerbation
[15]. In all patients asthma was controlled or nearly con-
trolled (group of severe asthmatics). Aspirin hypersensi-
tivity was diagnosed based on convincing history of
adverse reaction after use of nonsteroidal anti-inflamma-
tory drugs and in patients with unequivocal history it was
confirmed by bronchial challenge with lysine-aspirin. In
all patients skin prick tests with panel of 14 standard aller-
gens were performed. Oral and inhaled glucocorticoster-
oids (GCS) were withdrawn 12 hours, antileukotrienes 3
days and long acting beta 2 agonists 24 hours before
blood collection. Research have been carried out in com-
pliance with Helsinki Declaration. A study obtained
approval of ethical committee of Medical University of
Lodz. Every patient was informed about study protocol
and procedures and signed informed consent form.
Table 1: Characteristics of severe and non-severe asthmatics in two subpopulations of patients in whom SCF and c-kit serum levels 
were determined (* p < 0,05)
SCF group (n = 88) Sc-kit group (n = 63)
Non-severe asthma Severe asthma Non-severe asthma Severe asthma
Number of patients 32 56 22 41
Female/male 15/17 41/15 14/8 30/11
Age mean (range) 39,9 (19–57) 51 (23–74) 41 (24–64) 49,3 (22–74)
Patients with positive SPT 28 (87%) 39 (69%) 17 27
Aspirin hypersensitivity 15 (47%) 27 (48%) 5 18
Nasal polyps 13 (40%) 18 (32%) 4 10
FEV1% of predictive value (mean) 97% 73%* 98% 75%
Patients on inhaled GCS (n) 32 56 22 41
-mean daily dose
(mcg of budesonide)
612 1990* 540 2035*
Patients on oral GCS 03 3 *02 2 *
-mean daily dose
(mg of prednisone)
0 7,79* 0 3,8*
Total IgE (kU/ml) 322,4 +/- 87 317,9 +/- 62 302,3+/- 57 335,9 +/- 92
ECP (μg/ml) 8,4 +/- 1,76 12,92 +/- 1,45 10,16 +/- 1,26 12,21 +/- 1,97
Eosinophil count (cells/μl) 266 +/- 62 351,4 +/- 36,5 290,8 +/- 46,5 313,8 +/- 40,25BMC Pulmonary Medicine 2009, 9:27 http://www.biomedcentral.com/1471-2466/9/27
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Methods
Spirometry was carried according to ATS standards. Respi-
ratory function (flow-volume curve) was measured with
automatic spirometer (ABC Pneumo 2000RS, Poland) in
patients who were without short acting beta 2 agonists for
at least 8 h and long acting beta 2 agonists for at least 12
hours.
Blood (5 ml for serum) was collected by venipuncture,
serum was separated and frozen in -20°C. The concentra-
tions of SCF and sc-kit SCF in serum were measured by
ELISA method (R&D systems; Minneapolis, USA).
The level of ECP and total IgE were measured by immu-
noenzymatic method (Pharmacia, Uppsala, Sweden).
Total IgE and Eosinophil Cationic Protein(ECP) were
measured in serum with ImmunoCAP (Pharmacia Diag-
nostic, Sweden). Blood eosinophila (as a differential
count) was assessed after staining with Pappenheim's
method.
Statistical analysis
Data are presented as mean ± standard error mean. For
comparison of 3 groups of variables Kruskal Wallis
ANNOVA and post hoc Dunn tests were used. For com-
parison of 2 variables nonparametric unpaired 2-group
test (Mann- Whitney U test) was carried out. P < 0,05 was
considered statistically significant. Pearson correlation
coefficient was used to compare level of SCF and sc-kit
with FEV1% of predicted value, MEF% of predicted value
and dose of inhaled glucocorticosteroids received by the
patients.
Results
SCF serum levels
Mean serum SCF level in asthmatics (n = 88) was signifi-
cantly higher as compared to healthy controls (1010 +/-
37 pg/ml versus 799 +/- 33 pg/ml; p < 0,001). The level of
SCF was higher in the group of patients with severe
asthma as compared to patients with non-severe asthma
(1054 +/- 41 pg/ml vs 819 +/- 50 pg/ml; p < 0,01) (Fig 1).
When two subgroups of severe asthmatics: patients on
oral gluccocorticosteroids (SA GCS+, n = 30) and patients
not treated with oral gluccocorticosteroids (SA GCS-, n =
26) were analyzed, the SCF level was significantly higher
in both groups (1066 +/- 66,41 pg/ml and 1023 +/- 45,9
pg/ml) as compared to mild asthmatics (819,3 +/- 50,3; p
< 0,01) and healthy controls (815 +/- 36; p < 0,01) (Fig 2).
In the group of severe asthma there was no differences in
SCF level between patients on oral GCS (n = 33) and with-
Serum SCF concentrations in patients with severe asthma  (SA, n = 56) (* p < 0,001) and non-severe asthmatics (NSA, n  = 32) (& p < 0,01) as compared to healthy controls (HC, n =  21) Figure 1
Serum SCF concentrations in patients with severe 
asthma (SA, n = 56) (* p < 0,001) and non-severe 
asthmatics (NSA, n = 32) (& p < 0,01) as compared to 
healthy controls (HC, n = 21).
Serum SCF level in patients with severe asthma treated (SA  GCS+) and not treated (SA GSC-) with oral glucocorticos- teroids as compared to mild asthmatics (MA) (* p < 0,01) and  nonatopic healthy controls (HC) (& p < 0,01) Figure 2
Serum SCF level in patients with severe asthma 
treated (SA GCS+) and not treated (SA GSC-) with 
oral glucocorticosteroids as compared to mild asth-
matics (MA) (* p < 0,01) and nonatopic healthy con-
trols (HC) (& p < 0,01).BMC Pulmonary Medicine 2009, 9:27 http://www.biomedcentral.com/1471-2466/9/27
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out oral GCS (n = 23) (1066 +/- 66,41 pg/ml versus 1023
+/- 45,9 pg/ml; ns).
For the whole group of asthmatic patients (n = 88) SCF
level correlated with the dose of inhaled GCS taken by the
patients to achieve asthma control (R = 0,28; p < 0,01)
(Fig 3). SCF level did not correlate with FEV1% of pre-
dicted value, the number of eosinophils in peripheral
blood or with ECP level in the serum. The SCF level did
not differ between patients with or without aspirin hyper-
sensitivity, with or without nasal polyps and patients with
atopic and nonatopic asthma (table 2).
Soluble c-kit serum level
The mean serum level of sc-kit in asthmatics without
regard to asthma severity (n = 63) was similar to healthy
controls (p > 0,05). In patients with non-severe asthma
the mean sc-kit level (95,78 +/- 8,5 ng/ml) was higher as
compared to patients with severe asthma (62,0 +/- 4,0 ng/
ml; p < 0,01) and to healthy controls (57,7 +/- 4,18 ng/ml;
p < 0,05). There was no difference between mean sc-kit
level in patients with severe asthma and healthy controls
(Fig 4). When two subgroups of severe asthmatics:
patients on oral gluccocorticosteroids (SA GCS+, n = 21)
and patients not treated with oral gluccocorticosteroids
(SA GCS-, n = 19) were analyzed, the sc-kit level was sig-
nificantly lower in both groups (64, +/- 5,9 9 ng/ml and
58,71 +/- 5,3 ng/ml) as compared to mild asthmatics
(95,8 +/- 8,5; p < 0,01) (Fig 5). There was no differences
in sc-kit level between patients on oral GCS and without
oral GCS (mean 64, +/- 5,9 9 ng/ml versus 58,71 +/- 5,3
ng/ml; ns).
In asthmatic patients (n = 63) the level of sc-kit correlated
positively with FEV1% of predicted value (R = 0,45; p <
0,001) (Fig 6) and with MEF25% of predicted value (R =
0,33; p < 0,01) (Fig 7), but correlated inversely with the
dose of inhaled GCS taken by the patients (R = -0,26; p <
0,01) (Fig 8).
Sc-kit level was significantly higher in patients with non-
atopic asthma as compared to patients with atopic asthma
(87,00 +/- 8,02 ng/ml versus 67,50 +/- 5,03 ng/ml; p <
0,05) (Fig 9). Sc-kit level did not differ between the group
of patients with or without aspirin hypersensitivity (table
2), however sc-kit level was significantly higher in patients
with aspirin triad (n = 11) (74,3 ng/ml +/- 9 versus 53,8
+/- 4,9 ng/ml; p < 0,05) (Fig 10) and was significantly
higher in patients with nasal polyps (table 2).
There was no correlation between serum SCF and sc-kit
levels in patients with asthma, control subjects and in
combined group (n = 59; r = -0,04, ns).
Discussion
In this study we showed that serum level of SCF is higher
in patients with asthma as compared to healthy subjects
and is further increased in patients with severe refractory
asthma. In parallel patients with severe asthma had
decreased level of serum soluble c-kit as compared to non-
severe asthmatics. Despite differences between SCF levels
in patients with severe and non severe asthma serum SCF
did not correlate with markers of asthma severity such as
FEV1% and MEF% of predicted value, however it corre-
lated with dose of inhaled corticosteroids needed to
achieve asthma control.
Previous studies showed increased production of SCF in
different allergic disease like asthma, allergic rhinitis and
atopic dermatitis [5-8]. Expression of SCF and it's receptor
c-kit mRNA in airway epithelium of patients with asthma
was increased in comparison to healthy control airways
[5]. The studies on SCF mRNA expression in nasal mucosa
are unequivocal, one study showed overexpression of SCF
mRNA in the nasal mucosa of patients with allergic rhini-
tis [7,16] while the other did not find the differences in
the expression of SCF mRNA between patients with and
without allergic rhinitis [17].
Table 2: The results of SCF and c-kit concentrations in the supgroups og aspirin hypersensitive and tolerant patients, patients with and 
without nasal polyps and atopic and nonatopic asthmatics.
SCF (pg/ml) c-kit (ng/ml)
Aspirin hypersensitive 
(n = 42)
Aspirin tolerant (n = 46) P value Aspirin hypersensitive 
(n = 23)
Aspirin tolerant (n = 40) P value
959,1 +/- 44 980 +/- 50 Ns 76,9 +/- 6,8 71,7 +/- 5,7 ns
With nasal polyps (n = 33) Without nasal polyps 
(n = 55)
P value With nasal polyps (n = 14) Without nasal polyps 
(n = 49)
P value
928 +/- 42,4 992 +/- 47,8 Ns 83,5 +/- 80 70,3 +/- 51,6 0,049
Atopic (n = 67) Nonatopic (n = 21) P value Atopic (n = 44) Nonatopic (n = 19) P value
949,9 +/- 38 1033 +/- 65 ns 67,5 +/- 5,03 87 +/- 8,02 0,028BMC Pulmonary Medicine 2009, 9:27 http://www.biomedcentral.com/1471-2466/9/27
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Although the serum level of SCF in healthy controls and
patients with non- severe asthma was similar, the most
severe patients had significantly higher serum SCF con-
centration in comparison both to healthy control and
non-severe asthmatics. It is noticeable that despite aggres-
sive anti-inflammatory treatment in the group of severe
asthmatics (high doses of inhaled steroids, oral GCS, anti-
leukotriens) the level of SCF was significantly increased. It
has been demonstrated that at the beginning of the treat-
ment GCS can increase the level of SCF [18], however they
suppress the constitutive production of SCF [19]. Further-
more expression of SCF in asthmatic bronchi which is
higher in comparison to healthy controls, can be normal-
ized by treatment with inhaled glucocorticosteroids [20].
In contrast we did not see any difference in SCF serum lev-
els between asthmatics with and without oral GCS.
As in asthmatic subjects not only SCF but also its receptor
c-kit can be overexpressed on inflammatory cells we meas-
Correlation between SCF serum concentrations and dose of  inhaled steroids taken by the patients (n = 88) Figure 3
Correlation between SCF serum concentrations and 
dose of inhaled steroids taken by the patients (n = 
88).
Soluble c-kit in serum non-severe asthmatics (NSA, n = 22)  as compared to patients with severe asthma (SA, n = 41) (*p  <0,05) and healthy controls (HC, n = 15) (& p < 0,01) Figure 4
Soluble c-kit in serum non-severe asthmatics (NSA, n 
= 22) as compared to patients with severe asthma 
(SA, n = 41) (*p <0,05) and healthy controls (HC, n = 
15) (& p < 0,01).
Serum sc-kit level in patients with severe asthma treated (SA  GCS+) and not treated (SA GSC-) with oral glucocorticos- teroids as compared to mild asthmatics (MA) (& p < 0,01) Figure 5
Serum sc-kit level in patients with severe asthma 
treated (SA GCS+) and not treated (SA GSC-) with 
oral glucocorticosteroids as compared to mild asth-
matics (MA) (& p < 0,01). Sc-kit level in mild asthmatics as 
compared to healthy control subjects (* p < 0,01).
Correlation of FEV1 % of predicted value with sc-kit serum  level in asthmatic patients (n = 63) Figure 6
Correlation of FEV1 % of predicted value with sc-kit 
serum level in asthmatic patients (n = 63).BMC Pulmonary Medicine 2009, 9:27 http://www.biomedcentral.com/1471-2466/9/27
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ured the soluble c-kit in the serum of patients [5].
Although the level of sc-kit was higher in the group of
non-severe asthmatics as compared to healthy controls, in
severe asthmatics sc-kit level was similar to healthy con-
trols. Moreover, for the whole asthmatic group, the level
of sc-kit positively correlated with such markers of disease
severity as FEV1%, MEF25% of predicted value or the dose
of inhaled glucocorticosteroids needed to maintain
asthma control. It suggests that in non-severe asthmatics
sc-kit could have protective role, e.g. by blocking SCF and
therefore suppressing development of more severe
inflammatory process. On the other hand the lack of
increased sc-kit levels in patients with severe asthma could
reflect decreased capacity of their serum to neutralize
activity of SCF. Suggestion that, treatment with systemic
glucocorticosteroids or high doses of inhaled glucocorti-
costeroids could be responsible for decreased generation
of sc-kit is not likely since sc-kit levels were comparable in
the group of patients treated and non-treated with oral
GCS. Inhaled steroids seemed to suppress serum sc-kit lev-
els in asthmatic patients. It suggests that inhaled and oral
steroids may have different effect on serum sc-kit levels
since patients treated and non-treated with oral GCS had
similar sc-kit levels.
Our observations in line with study in patients with atopic
dermatitis [8] which showed higher serum levels of both
Correlation of MEF25% with serum soluble c-kit in patients  with asthma (n = 63) Figure 7
Correlation of MEF25% with serum soluble c-kit in 
patients with asthma (n = 63).
Correlation of the dose of inhaled budesonide with soluble c- kit serum levels in patients with asthma (n = 63) Figure 8
Correlation of the dose of inhaled budesonide with 
soluble c-kit serum levels in patients with asthma (n 
= 63).
Soluble c-kit in serum of patients with atopic and nonatopic  asthma Figure 9
Soluble c-kit in serum of patients with atopic and 
nonatopic asthma.
Soluble c-kit in serum levels in patients with asthma, aspirin  hypersensitivity and nasal polyps (ASA group, n = 11) and in  patients with asthma without aspirin hypersensitivity and  nasal polyps (ATA group, n = 20) (* p < 0,05) Figure 10
Soluble c-kit in serum levels in patients with asthma, 
aspirin hypersensitivity and nasal polyps (ASA group, 
n = 11) and in patients with asthma without aspirin 
hypersensitivity and nasal polyps (ATA group, n = 20) 
(* p < 0,05).BMC Pulmonary Medicine 2009, 9:27 http://www.biomedcentral.com/1471-2466/9/27
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SCF and sc-kit as compared to control subjects and posi-
tive correlation of sc-kit levels with atopic dermatitis
severity index SCORAD. On the other hand s-kit was
decreased in patients with systemic lupus erythematosus
and negatively correlated with disease severity [21].
We were not able to correlate the level of SCF with aspirin
hypersensitivity or concomitant nasal polyposis, although
in previous study the increased expression of SCF within
the nasal polyps of patients with asthma and aspirin
hypersensitivity was reported [9]. It suggests that serum
levels of SCF may not fully reflect local production of SCF
in the inflammatory tissue. In contrast to previous study
SCF levels in peripheral blood were significantly higher
than in healthy controls only in the group of patients with
allergic asthma, SCF levels did not differ significantly
between patients with allergic and nonallergic asthma [6]
which was also observed in our study.
Conclusion
Our study demonstrated that serum levels of SCF, a pleio-
tropic cytokine influencing development of two major cell
lines in asthmatic inflammation- mast cells and eosi-
nophils is elevated in patients with most severe asthma
and may be important in pathogenesis of airway obstruc-
tion. Furthermore it seems that physiological down regu-
lation of this cytokine by soluble kit receptor is also
impaired in patients with severe asthma, thus modifying
the SCF/c-kit interaction in asthmatics subjects.
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